ClinicalTrials.gg
RecruitingNCT07224581Updated Nov 12, 2026

Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder

A Phase 3 interventional study of Radiprodil and Placebo in GRIN-related Neurodevelopmental Disorder, sponsored by GRIN Therapeutics, Inc.. Recruiting at 62 sites in 13 countries. Open to participants aged 1 Month to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by GRIN Therapeutics, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Nov 12, 2026First sites in Australia, Japan and South Korea28 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
1 Month to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 99 studies in Neurodevelopmental Disorders with a site in United States — 36 open to participants now, 52 under way, 9 of them phase 3. Neurodevelopmental Disorders · United States.

Planned enrollment
29th of 60
100 · median 100
Started
2026
with 9 others
Phase 3
11 of 99
3 open now
Primary completion
2027-05
later than 21 of 51 live
Registered
90th of 99
by date

Among the 99 studies in Neurodevelopmental Disorders with a site in United States, this one is the 29th largest by planned enrollment of the 60 interventional ones that give a count, is one of 10 that started in 2026, is one of 11 in phase 3, reaches primary completion later than 21 of the 51 other live ones, and was the 90th registered.

Neurodevelopmental Disorders

353 studies on the registry are indexed under Neurodevelopmental Disorders; 142 are open to participants now.

Browse Neurodevelopmental Disorders studies →

Open to participants now

36 of the 99 studies in Neurodevelopmental Disorders with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 100 Neurodevelopmental Disorders studies recruiting now, 20 (20%) set no upper age limit and 76 (76%) stop at 75 or younger; 86 take children under 18; 31 take healthy volunteers.

This study: 1 Month to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Neurodevelopmental Disorders with a site in United States, or all of them as a file.
02

Study summary

The Phase 3 portion of Study RAD-GRIN-101 is a multinational, multicenter, randomized, double-blind, placebo-controlled trial followed by an open-label extension to evaluate the efficacy and safety of radiprodil in participants with GRIN-related neurodevelopmental disorder (GRIN-NDD) with a gain-of-function (GoF) genetic variant.

This study will enroll two cohorts: one cohort of participants with a minimal number of countable motor seizures (with or without behavioral symptoms) (Phase 3 Cohort 1: Qualifying Seizures Cohort); and a second cohort with disease symptoms but no seizures or fewer seizures than required for the Qualifying Seizures Cohort (Phase 3 Cohort 2: Without Qualifying Seizures Auxiliary Cohort).

Participants in each cohort will be randomized 1:1 to receive active drug (radiprodil) or matching placebo (Part A). Following completion of Part A, all eligible participants (including those previously on placebo) may continue into the open-label extension period (Part B) to receive radiprodil.

The placebo-controlled portion is expected to be approximately 16 weeks for participants in Phase 3 Cohort 1 and 28 weeks for participants in Phase 3 Cohort 2.

The study will evaluate the effect of radiprodil on seizures and non-seizure symptoms and assess safety.

Read the detailed description

Participants are assigned in a 1:1 ratio to receive either radiprodil or placebo during Part A with the opportunity to receive radiprodil in the Open-Label Extension, Part B. The dosing regimen includes a fixed titration schedule over 4 weeks.

This study is divided into the following parts:

Part A: Randomized, double-blind, placebo-controlled

  • Screening/Observation Period: To assess eligibility
  • Titration Period (approximately 4 weeks): Titration of radiprodil or placebo to target dose
  • Maintenance Period (Part A): Target dose of radiprodil or placebo maintained for 12 weeks (Phase 3 Cohort 1) or 24 weeks (Phase 3 Cohort 2)
  • Tapering and Follow-up Period: Gradual decrease and Follow-up Period for participants not entering Part B

Part B: Open-label safety follow-up period

  • Open-Label Treatment Period: Participants will continue to receive radiprodil until such time as either the participant withdraws/is withdrawn from the study, sponsor terminates the study, or market access is available
  • Tapering and Follow-up Period: Gradual decrease and follow-up observation period for participants upon leaving the study
03

Conditions studied

  • GRIN-related Neurodevelopmental Disorder

Keywords

  • Beeline
  • GRIN1
  • GRIN2A
  • GRIN2B
  • GRIN2D
  • GRIN-NDD
04

Who can participate

Ages eligible
1 Month to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part A, Participant:

  • Diagnosed with GRIN-NDD with GRIN1, GRIN2A, GRIN2B, or GRIN2D gene variants known to result in GoF of the NMDA receptor
  • Phase 3 Cohort 1 (Qualifying Seizures Cohort) ONLY: Experiencing at least 1 CMS per week and ≥4 CMS (generalized or focal) during screening
  • With history of inadequate response to at least 2 standard antiseizure medications (ASMs)
  • Phase 3 Cohort 2 (Without Qualifying Seizures Auxiliary Cohort) ONLY: With significant neurodevelopmental symptoms and a GRIN-CGI-S score ≥4
  • On a stable dose of standard ASMs for at least 4 weeks prior to screening and should remain on stable doses throughout study participation
  • On stable nonpharmacological treatments such as ketogenic diet and should remain stable throughout study participation

Part B:

- Participant has completed Part A and is eligible to continue study participation according to the judgement of the investigator and sponsor.

Exclusion criteria

Exclusion Criteria:

PART A, Participant:

  • Has medical, neurologic, or psychiatric condition and/or behavioral disorder (including those related to GRIN-NDD) that would preclude or jeopardize participant's safe participation or study drug administration or the conduct of the study according to the judgement of the investigator or sponsor.
  • Is receiving >4 standard ASMs at screening
  • Has a body weight of less than 5 kg at screening

Part B:

- Participant has clinically relevant medical, neurologic, or psychiatric condition and/or behavioral disorder (including those related to GRIN-NDD) that would preclude or jeopardize participant's safe participation of study drug administration or the conduct of the study according to the judgement of the investigator or sponsor.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Radiprodil

    Liquid suspension of radiprodil, at varying concentrations depending on participant's weight. The following dose-escalation regimen (twice daily \[BID\]) will be used: Titration Period Visit 1 (Visit T1): Dose 1, Visit T2: Dose 2, Visit T3: Dose 3, Visit T4: Maintenance Dose.

    Drug: Radiprodil

  • Placebo comparator
    Placebo

    Liquid suspension of placebo matching radiprodil oral suspension and dose-escalation regimen.

    Drug: Placebo

Interventions

  • Radiprodil oral suspension

  • DrugPlacebo

    Placebo-to-match radiprodil oral suspension

06

What researchers measure

Primary outcomes

  1. Part A - Phase 3 Cohort 1 (Qualifying Seizures Cohort): Countable motor seizures (CMS)

    Time frame: 12 weeks

  2. Part A - Phase 3 Cohort 2 (Without Qualifying Seizures Auxiliary Cohort): Adverse events (AEs), serious adverse events (SAEs), and adverse drug reactions (ADRs)

    Time frame: 24 weeks

  3. Part B - Open-Label Extension: Adverse events (AEs), serious adverse events (SAEs), and adverse drug reactions (ADRs)

    Time frame: Average of 2 years

Secondary outcomes

  1. Part A - Phase 3 Cohort 1 (Qualifying Seizures Cohort): Proportion of participants with ≥50% reduction in CMS

    Time frame: 12 weeks

  2. Part A - Phase 3 Cohort 1 (Qualifying Seizures Cohort): CMS-free days

    Time frame: 12 weeks

  3. Part A - Phase 3 Cohort 1 (Qualifying Seizures Cohort): GRIN-NDD-specific Clinical Global Impression - Change [CGI-C] scale

    Time frame: 12 weeks

  4. Part A - Phase 3 Cohort 1 (Qualifying Seizures Cohort): Aberrant Behavior Checklist-Community (ABC-2C) irritability subscale

    Time frame: 12 weeks

  5. Part A - Phase 3 Cohort 1 (Qualifying Seizures Cohort): Vineland Adaptive Behavior Scale 3rd edition (VABS-3) daily living personal subdomain

    Time frame: 12 weeks

  6. Part A - Phase 3 Cohort 2 (Without Qualifying Seizures Auxiliary Cohort): GRIN-CGI-C scale

    Time frame: 24 weeks

  7. Part A - Phase 3 Cohort 2 (Without Qualifying Seizures Auxiliary Cohort): ABC-2C irritability subscale

    Time frame: 24 weeks

  8. Part A - Phase 3 Cohort 2 (Without Qualifying Seizures Auxiliary Cohort): VABS-3 daily living personal subdomain

    Time frame: 24 weeks

  9. PART B - Open-Label Extension: CMS frequency

    Time frame: average of 2 years

  10. PART B - Open-Label Extension: CMS-free days

    Time frame: average of 2 years

  11. PART B - Open-Label Extension: ABC-2C irritability subscale

    Time frame: average of 2 years

  12. PART B - Open-Label Extension: VABS-3 daily living personal subdomain score

    Time frame: average of 2 years

  13. PART B - Open-Label Extension: GRIN-CGI-C scale

    Time frame: average of 2 years

07

Study locations

61 of 62 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for May 2027, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2025
First posted
Nov 4, 2025
StartActual
Jan 5, 2026
Primary completionEst.
May 2027
CompletionEst.
Jul 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
28 sites added — first sites in Australia, Japan and South Korea
Show 28 added (6 France, 6 Japan, 4 United States, 3 Italy, 2 Australia, 2 Germany, 1 Belgium, 1 Poland, 1 South Korea, 1 Spain, 1 United Kingdom)
  • Children's National Medical Center · Washington D.C., United States
  • Duke University Health System · Durham, United States
  • Cincinnati Children's Hospital Medical Center · Cincinnati, United States
  • Children's Health Specialty Center, Dallas · Dallas, United States
  • Queensland Children's Hospital · South Brisbane, Australia
  • Austin Health · Heidelberg, Australia
  • University Hospital Antwerp · Edegem, Belgium
  • CHU Angers · Angers, France
  • Hospices Civils de Lyon · Bron, France
  • CHU de Dijon · Dijon, France
  • AP HM Hopital d'enfants de la Timone · Marseille, France
  • Hopital Necker Enfants Malades (APHP) · Paris, France
  • Hopital des Enfants ; CHU Toulouse · Toulouse, France
  • Universitatsklinikum Leipzig · Leipzig, Germany
  • Universitatsklinikum OWL der Universitat Bielefeld · Bielefeld, Germany
  • Azienda Unita Sanitaria Locale Di Bologna, IRCCS lstituto Delle Scienze Neurologiche · Bologna, Italy
  • Fondazione IRCCS lstituto Neurologico Carlo Besta · Milan, Italy
  • Fondazione lstituto Neurologico Nazionale Casimiro Mondino · Pavia, Italy
  • Kanagawa Children's Medical Center · Minami, Japan
  • University of Miyazaki Hospital · Miyazaki, Japan
  • Nagoya University Hospital · Nagoya, Japan
  • National Hospital Organization Nishiniigata Chuo Hospital · Niigata, Japan
  • Local Incorporated Administrative Agency Osaka City Hospital Organization Osaka City General Hospital · Osaka, Japan
  • Showa Medical University Hospital · Shibukawa, Japan
  • lnstytut Pomnik Centrum Zrowia Dziecka · Warsaw, Poland
  • Seoul National University Hospital · Seoul, South Korea
  • Hospital Universitario Infantil Nino Jesus · Madrid, Spain
  • Great Ormond Street Hospital for Children NHS Foundation · London, United Kingdom
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    28 sites added — first sites in Australia, Japan and South Korea
    Show 28 added (6 France, 6 Japan, 4 United States, 3 Italy, 2 Australia, 2 Germany, 1 Belgium, 1 Poland, 1 South Korea, 1 Spain, 1 United Kingdom)
    • Children's National Medical Center · Washington D.C., United States
    • Duke University Health System · Durham, United States
    • Cincinnati Children's Hospital Medical Center · Cincinnati, United States
    • Children's Health Specialty Center, Dallas · Dallas, United States
    • Queensland Children's Hospital · South Brisbane, Australia
    • Austin Health · Heidelberg, Australia
    • University Hospital Antwerp · Edegem, Belgium
    • CHU Angers · Angers, France
    • Hospices Civils de Lyon · Bron, France
    • CHU de Dijon · Dijon, France
    • AP HM Hopital d'enfants de la Timone · Marseille, France
    • Hopital Necker Enfants Malades (APHP) · Paris, France
    • Hopital des Enfants ; CHU Toulouse · Toulouse, France
    • Universitatsklinikum Leipzig · Leipzig, Germany
    • Universitatsklinikum OWL der Universitat Bielefeld · Bielefeld, Germany
    • Azienda Unita Sanitaria Locale Di Bologna, IRCCS lstituto Delle Scienze Neurologiche · Bologna, Italy
    • Fondazione IRCCS lstituto Neurologico Carlo Besta · Milan, Italy
    • Fondazione lstituto Neurologico Nazionale Casimiro Mondino · Pavia, Italy
    • Kanagawa Children's Medical Center · Minami, Japan
    • University of Miyazaki Hospital · Miyazaki, Japan
    • Nagoya University Hospital · Nagoya, Japan
    • National Hospital Organization Nishiniigata Chuo Hospital · Niigata, Japan
    • Local Incorporated Administrative Agency Osaka City Hospital Organization Osaka City General Hospital · Osaka, Japan
    • Showa Medical University Hospital · Shibukawa, Japan
    • lnstytut Pomnik Centrum Zrowia Dziecka · Warsaw, Poland
    • Seoul National University Hospital · Seoul, South Korea
    • Hospital Universitario Infantil Nino Jesus · Madrid, Spain
    • Great Ormond Street Hospital for Children NHS Foundation · London, United Kingdom
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07224581
Lead sponsor
GRIN Therapeutics, Inc.
Responsible party
Sponsor
First posted
Nov 4, 2025
Start date
Jan 5, 2026
Primary completion
May 2027 (estimated)
Completion
Jul 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Clinical Operations
Contact
ClinicalTrials@GrinTherapeutics.com
+1-877-225-0014
Stephen Tisi
study director · GRIN Therapeutics, Inc.
Russell Chin
study director · GRIN Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Radiprodil

Start the discussion